New drug for cancer patients with ‘limited’ treatment options enters clinical trial

Experimental Novartis radiopharma drug shows promise in early study

Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients

An experimental drug called daraxonrasib has become the first treatment to substantially extend the lives of pancreatic cancer patients in a

New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'

Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma

Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch

The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment

Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds

Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug